Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Viekirax (ombitasvir, paritaprevir, ritonavir) with or without Exviera (dasubuvir) - Important Safety Information from AbbVie Ltd. as approved by the HPRA
Notice type:
3rd Party Publications
Date:
05/01/2016
Problem Or Issue:
Important Safety Information communication from AbbVie Ltd. - Viekirax, with or without Exviera: not recommended in Child-Pugh B patients.
Important Safety Information - Viekirax (ombitasvir, paritaprevir, ritonavir) with or without Exviera (dasubuvir)
« Back
Date Printed: 20/09/2024